当前位置： SCI文献检索 > BMC INFECTIOUS DISEASES期刊下所有文献 > Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.

Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.

Abstract：

BACKGROUND:Antiretroviral therapy markedly reduced mortality in HIV-infected individuals. However, in the previous studies, up to 50% of patients are compelled to modify their regimen in middle and low-income countries where salvage drug is still limited. This cohort study aimed to investigate the incidence and predictors of regimen modification from the first-line antiretroviral regimen in northern Thailand. METHODS:All HIV-infected patients starting antiretroviral therapy (ART) with generic drug (GPOvir®; stavudine, lamivudine and nevirapine) at a governmental hospital in northern Thailand from 2002 to 2007 were recruited. Baseline characteristics and detailed information of regimen modification until the end of 2010 were ascertained from cohort database and medical charts. As a potential genetic predictor of regimen modification, HLA B allele was determined by bead-based array hybridization (WAKFlow® HLA typing kit). We investigated predictors of the regimen modification using Cox's proportional hazard models. RESULTS:Of 979 patients, 914 were eligible for the analysis. The observed events of regimen modification was 377, corresponding to an incidence 13.8/100 person-year-observation (95% CI:12.5-15.3) over 2,728 person years (PY) follow up. The main reasons for regimen modification were adverse effects (73.5%), especially lipodystrophy (63.2%) followed by rash (17.7%). Sixty three patients (17.1%) changed the regimen due to treatment failure. 2% and 19% of patients had HLA-B*35:05 and B*4001, respectively. HLA-B*35:05 was independently associated with rash-related regimen modification (aHR 7.73, 95% CI:3.16-18.9) while female gender was associated with lipodystrophy (aHR 2.11, 95% CI:1.51-2.95). Female gender (aHR 0.54, 95% CI: 0.30-0.96), elder age (aHR 0.56, 95% CI: 0.32-0.99) and having HLA-B*40:01 (aHR 0.29, 95% CI: 0.10-0.82) were protective for treatment failure related modification. CONCLUSION:HLA-B*35:05 and female gender were strong predictors of regimen modification due to rash and lipodystrophy, respectively. Female gender, elder age, and having HLA-B*40:01 had protective effects on treatment failure-related regimen modification. This study provides further information of regimen modification for future tailored ART in Asia.

journal_name

BMC Infect Dis

journal_title

BMC infectious diseases

authors

Tsuchiya N,Pathipvanich P,Wichukchinda N,Rojanawiwat A,Auwanit W,Ariyoshi K,Sawanpanyalert P

doi

10.1186/s12879-014-0565-5

subject

Has Abstract

pub_date

2014-10-30 00:00:00

pages

565

issn

1471-2334

pii

s12879-014-0565-5

journal_volume

pub_type

杂志文章

在线工具

Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.